On December 5, 2022 Herantis Pharma Plc ("Herantis") reported that as notified earlier on December 1, 2022, it has applied for delisting of its shares from Nasdaq First North Growth Market Sweden ("Nasdaq FN GM Sweden") (Press release, Herantis Pharma, DEC 5, 2022, View Source;approved-delisting-application-regarding-the-secondary-listing-on-the-nasdaq-first-,c3677358 [SID1234624763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nasdaq Stockholm AB approved the application December 2, 2022 and decided to delist the shares of Herantis (trading code HRNTS, ISIN code FI4000087861) from Nasdaq FN GM Sweden.

The last day of trading in the shares of Herantis on Nasdaq First North Growth Market Sweden shall be January 31, 2023.

The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy.

Aqurat Fondkommission AB acts as Herantis’ Issuing Agent and will coordinate the conversion process:

Instructive letter will be distributed to directly registered shareholders and to all custodians
The instructive letter explains the conversion process and actions to be taken
Cross-border settlement will be done weekly

Shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB ([email protected]) for more information.

On December 5, 2022 Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, reported positive new data regarding overall survival results in its HER-Vaxx HERIZON study as provided in an oral presentation at the ESMO (Free ESMO Whitepaper) Asia Congress 2022 held in Singapore (Press release, Imugene, DEC 5, 2022, View Source [SID1234624757]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speaking to the Congress on Sunday 4 December 2022, principal investigator Marina Maglakelidze outlined
the study design, information regarding demographics and characteristics of the 36 patients in the trial,
and data covering safety and adverse events.

Key conclusions of the overall survival benefit of HER-Vaxx included:

• HER-Vaxx + chemotherapy showed a statistically significant 42% overall survival benefit compared
to chemotherapy alone (13.9 vs 8.3 months)
• Duration of response is longer in the HER-Vaxx + chemotherapy arm over chemotherapy alone (30
vs 19 weeks)
• Vaccination with HER-Vaxx induced persistent HER-2 specific antibodies which correlated with
clinical response as proof of concept for a first-in-class B-cell immunotherapy based on HER-2
peptides
• No significant additive toxicity was seen when HER-Vaxx was administered in combination with
chemotherapy

The full presentation provided at ESMO (Free ESMO Whitepaper) can be viewed at: View Source

The oral presentation and abstract, number 74MO, was titled ‘HERIZON Overall Survival Results: A study of
IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2
Overexpressing Metastatic or Advanced Gastric/GEJ Cancer’.

The HERIZON study was a Phase 2 clinical trial of Imugene’s HER-Vaxx technology in Her-2/Neu
overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer
immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric,
breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell
epitopes derived from the extracellular domain of HER2/neu.

On December 4, 2022 Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, reported that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic (R/M) cervical cancer were released on 4 December 2022 in oral presentation (Proffered Paper, 179O) at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Asia Congress 2022 (Press release, Qilu Pharmaceutical, DEC 4, 2022, View Source [SID1234624756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Patients with R/M cervical cancer have a poor prognosis and the 5-year survival rate is less than 20%. Although immune checkpoint inhibitors (ICIs) have shown clinical activity in R/M cervical cancer as second-line treatment, the studies on ICIs given in the first-line setting are limited.

QL1604 is a highly selective, humanized monoclonal antibody that binds to PD-1. This is a phase II, open-label, single-arm study of QL1604 plus chemotherapy in patients with R/M cervical cancer (NCT04864782). Eligible patients received QL1604 200 mg plus chemotherapy (paclitaxel and cisplatin/carboplatin) once every 3 weeks (Q3W) for up to 6 cycles, and then QL1604 200 mg Q3W for maintenance therapy until disease progression or other discontinuation events.

As of the data cutoff, 46 patients with R/M cervical cancer and naïve to systemic treatment were enrolled at 12 sites in China. Twenty (43.5%) patients previously underwent surgery and 40 (87%) patients previously received radiotherapy. Thirty-nine (84.8%) patients had recurrent disease and 7 (15.2%) patients had stage IV disease.

The median follow-up time was 12.91 months. A total of 8 (17.4%) patients achieved complete response and 19 (41.3%) patients achieved partial response, resulting in an objective response rate of 58.7% (27/46). The disease control rate was 84.8% (39/46). The median duration of response was 9.6 months (95% CI: 5.5, NE). The median progression-free survival was 8.1 months (95% CI: 5.7, 14.0). The overall survival was not reached.

QL1604 plus chemotherapy demonstrated a manageable safety profile, which was consistent with that reported for chemotherapy or anti-PD-1 therapy. The most common treatment-related adverse event was white blood cell count decreased.

Ms. Xiaoyan Kang, Head of Qilu Pharmaceutical clinical research center, stated, "We are pleased to release the latest study results of QL1604 plus chemotherapy as first-line treatment for patients with advanced cervical cancer. QL1604 plus chemotherapy showed promising antitumor activity and manageable safety profile as first-line treatment for women with R/M cervical cancer. Further investigations in this setting are ongoing.

On December 3, 2022 Philogen reported its attendance at the Antibody Engineering & Therapeutics 2022.
Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled "Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs): A Comparative Evaluation (Press release, Philogen, DEC 3, 2022, View Source [SID1234624754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please follow the link below for more information
Antibody Engineering & Therapeutics 2022

On December 2, 2022 Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), reported that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium (SABCS) which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting which will take place December 10 – December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. In-person and virtual meetings may be scheduled directly with Molecular Templates (Press release, Molecular Templates, DEC 2, 2022, View Source [SID1234624758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

45th Annual San Antonio Breast Cancer Symposium (SABCS)

Format: Poster presentation
Title/Poster Number: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results, Poster Number OT2-11-01
Time/Date: 5:00 – 6:15 PM CST, Wednesday December 7, 2022
Location: Hall 1, Henry B. Gonzalez Convention Center, San Antonio, TX and accessible via corporate website
64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting

Format: One-on-one meetings
Dates: December 10, 2022 – December 13, 2022
Location: Ernest N. Morial Convention Center, New Orleans, LA and Virtual